Next Article in Journal
A Systematic Literature Review for Evidence of Aphanizomenon flos-aquae Toxigenicity in Recreational Waters and Toxicity of Dietary Supplements: 2000–2017
Next Article in Special Issue
Novel Applications of OnabotulinumtoxinA in Lower Urinary Tract Dysfunction
Previous Article in Journal
Staphylococcus aureus Toxins and Their Molecular Activity in Infectious Diseases
Previous Article in Special Issue
Detection of Clostridium tetani Neurotoxins Inhibited In Vivo by Botulinum Antitoxin B: Potential for Misleading Mouse Test Results in Food Controls
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessArticle
Toxins 2018, 10(7), 253;

Early AbobotulinumtoxinA (Dysport®) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study

Centre for Neurodiagnostic and Therapeutic Services (CNS), Metropolitan Medical Centre, Manila 1012, Philippines
Department of Neurology & Psychiatry, Faculty of Medicine and Surgery, University of Santo Tomas, Manila 1008, Philippines
Ipsen Group, Boulogne-Billancourt, 92100 Paris, France
Division of Neurology, Department of Medicine, University of Malaya Medical Centre, Kuala Lumpur 59100, Malaysia
Department of Rehabilitation Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
Department of Rehabilitation Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia
Department of Rehabilitation Medicine, Tan Tock Seng Hospital, Novena 308433, Singapore
Author to whom correspondence should be addressed.
Received: 29 May 2018 / Revised: 11 June 2018 / Accepted: 11 June 2018 / Published: 21 June 2018
Full-Text   |   PDF [1108 KB, uploaded 21 June 2018]   |  


The ONTIME study investigated whether early post-stroke abobotulinumtoxinA injection delays appearance or progression of upper limb spasticity (ULS) symptoms. ONTIME (NCT02321436) was a 28-week, exploratory, double-blind, randomized, placebo-controlled study of abobotulinumtoxinA 500U in patients with ULS (Modified Ashworth Scale [MAS] score ≥ 2) 2–12 weeks post-stroke. Patients were either symptomatic or asymptomatic (only increased MAS) at baseline. Primary efficacy outcome measure: time between injection and visit at which re-injection criteria were met (MAS ≥ 2 and ≥1, sign of symptomatic spasticity: pain, involuntary movements, impaired active or passive function). Forty-two patients were randomized (abobotulinumtoxinA 500U: n = 28; placebo: n = 14) with median 5.86 weeks since stroke. Median time to reach re-injection criteria was significantly longer for abobotulinumtoxinA (156 days) than placebo (32 days; log-rank: p = 0.0176; Wilcoxon: p = 0.0480). Eleven (39.3%) patients receiving abobotulinumtoxinA did not require re-injection for ≥28 weeks versus two (14.3%) in placebo group. In this exploratory study, early abobotulinumtoxinA treatment significantly delayed time to reach re-injection criteria compared with placebo in patients with post-stroke ULS. These findings suggest an optimal time for post-stroke spasticity management and help determine the design and sample sizes for larger confirmatory studies. View Full-Text
Keywords: abobotulinumtoxinA; botulinum toxin type A; upper limb spasticity; post-stroke; early use; ONTIME abobotulinumtoxinA; botulinum toxin type A; upper limb spasticity; post-stroke; early use; ONTIME

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Rosales, R.L.; Balcaitiene, J.; Berard, H.; Maisonobe, P.; Goh, K.J.; Kumthornthip, W.; Mazlan, M.; Latif, L.A.; Delos Santos, M.M.D.; Chotiyarnwong, C.; Tanvijit, P.; Nuez, O.; Kong, K.H. Early AbobotulinumtoxinA (Dysport®) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study. Toxins 2018, 10, 253.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top